GLAXO · NSE
GlaxoSmithKline Pharmaceuticals Limited
₹2,838.8
+1.39% (+₹38.9)
Prev. close
₹2,799.9
Volume
1,25,265
Delivery %
70.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Bhushan Akshikar
Headquarters
Mumbai
Employees
3,103
Website
india-pharma.gsk.comExchange
View on NSE ↗Key stats
Market cap
₹48,090.99 Cr
P/E ratio (TTM)
45.1
Dividend yield
2.04%
EPS (TTM)
₹63.00
Beta (1Y · daily vs NIFTY 50)
0.46
Beta (5Y · monthly vs NIFTY 50)
0.48
Shares float
4.13 Cr
EPS · quarter ended Jun 2026
₹14.00
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,198.86 Cr | ₹3,278.03 Cr | ₹3,251.72 Cr | ₹3,453.71 Cr | ₹3,726.03 Cr | ₹3,821.67 Cr | |
| EBITDA | ₹633.31 Cr | — | ₹903.98 Cr | ₹887.67 Cr | ₹1,327.98 Cr | ₹1,475.18 Cr |
| ₹358.15 Cr | ₹1,695.00 Cr | ₹610.69 Cr | ₹589.96 Cr | ₹927.58 Cr | ₹1,035.98 Cr | |
| Diluted EPS | ₹21.14 | ₹100.04 | ₹36.05 | ₹34.83 | — | ₹61.15 |
Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
EBITDA for Mar 2021 could not be independently verified against the company's own annual report: this page shows ₹633.31 Cr while the annual report gives ₹805.91 Cr (27.3% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹736.26 Cr) and EBITDA for Mar 2022 (the annual report alone gives ₹837.66 Cr) are left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,115.00 Cr | ₹4,633.00 Cr | ₹3,327.00 Cr | ₹3,557.00 Cr | ₹4,108.00 Cr | ₹4,324.00 Cr | |
| ₹34.63 Cr | ₹20.08 Cr | ₹15.54 Cr | ₹18.67 Cr | ₹9.95 Cr | ₹33.27 Cr | |
| Stockholders' equity | ₹1,478.00 Cr | ₹2,663.00 Cr | ₹1,741.00 Cr | ₹1,777.00 Cr | ₹1,951.00 Cr | ₹2,267.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹578.00 Cr | ₹811.00 Cr | ₹484.00 Cr | ₹582.00 Cr | ₹1,290.00 Cr | ₹903.00 Cr | |
| Investing cash flow | ₹418.58 Cr | ₹-405.50 Cr | ₹807.85 Cr | ₹8.72 Cr | ₹-45.80 Cr | ₹396.98 Cr |
| ₹-696.00 Cr | ₹-524.00 Cr | ₹-1,543.00 Cr | ₹-562.00 Cr | ₹-769.00 Cr | ₹-737.00 Cr | |
| Capital expenditure | ₹-44.00 Cr | ₹-35.00 Cr | ₹-44.00 Cr | ₹-31.00 Cr | ₹-23.00 Cr | ₹-55.00 Cr |
| End cash position | ₹405.19 Cr | ₹286.19 Cr | ₹34.94 Cr | ₹64.17 Cr | ₹538.85 Cr | ₹1,102.05 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 75.00% |
| Public | 25.00% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| GlaxoSmithKline Pharmaceuticals Limited | ₹48,385.75 Cr | ₹2,799.9 | 45.2 | 21.34 | 45.7% | 0.01 | +2.2% | +2.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
31 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.